Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Fain

Pulmonary Disease Birmingham, AL Medical Doctor

NPI 1174882310 CMS profile 4437314

619 19Th St S, Birmingham, AL 35249

Open in the dashboard

General payments

$18,037

822 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Fain of Birmingham, AL is reported in the CMS Open Payments database as having received $18,037 across 822 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,707 162
2024 General $4,049 120
2023 General $2,786 131
2022 General $2,138 106
2021 General $1,614 85
2020 General $1,240 72
2019 General $2,503 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Fain
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jason Fain were reported at $3,707. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jason Fain Pulmonary Disease median Middle half National median
2019 $2,503 $377 $109–$1,340 $163
2020 $1,240 $230 $56–$907 $114
2021 $1,614 $269 $68–$1,072 $132
2022 $2,138 $390 $100–$1,457 $149
2023 $2,786 $419 $114–$1,659 $160
2024 $4,049 $476 $123–$1,818 $164
2025 $3,707 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,593 153 payments
  2. AstraZeneca Pharmaceuticals LP $2,211 115 payments
  3. Intuitive Surgical, Inc. $1,751 7 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,293 65 payments
  5. Mallinckrodt Hospital Products Inc. $1,281 53 payments
  6. Regeneron Healthcare Solutions, Inc. $842 45 payments
  7. Grifols USA, LLC $777 35 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $767 34 payments
  9. Merck Sharp & Dohme Corporation $558 28 payments
  10. United Therapeutics Corporation $498 23 payments
  11. Other $5,466 264 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,133 813 payments
  2. Education $1,737 7 payments
  3. Travel and Lodging $166 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,751 7 payments
  2. TRELEGY ELLIPTA $1,706 95 payments
  3. ACTHAR $1,281 53 payments
  4. FASENRA $801 34 payments
  5. Prolastin-C Liquid $777 35 payments
  6. GLASSIA $753 33 payments
  7. NUCALA $686 43 payments
  8. DUPIXENT $632 36 payments
  9. OFEV $584 30 payments
  10. SPIRIVA RESPIMAT $533 34 payments
  11. Other $9,937 509 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

875

Median for Pulmonary Disease: 936

Drug cost

$427,409

Median for Pulmonary Disease: $487,987

Branded share of claims

93.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 202 $150,127
Dupixent Syringe Dupilumab Brand 21 $82,105
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 84 $52,181
Breo Ellipta Fluticasone/Vilanterol Brand 114 $51,399
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 47 $21,817
Spiriva Respimat Tiotropium Bromide Brand 33 $18,434
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 28 $15,803
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 19 $10,989
Advair Hfa Fluticasone Propion/Salmeterol Brand 25 $8,679
Symbicort Budesonide/Formoterol Fumarate Brand 16 $5,030

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$85,461

Medicare's payments for the services billed

Medicare patients

390

Average age 76

Services billed

1,155

200 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 52%
Chronic kidney disease 51%
COPD 48%
Heart failure 46%
Diabetes 45%
Atrial fibrillation 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
$292 — —
TRELEGY ELLIPTA
$279 202 —
DUPIXENT
$265 21 —
Prolastin-C Liquid
$167 — —
OFEV
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

822 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record